RenovoRx (NasdaqCM:RNXT) Conference Transcript

Summary of RenovoRx Conference Call (November 20, 2025) Company Overview - Company: RenovoRx (NasdaqCM:RNXT) - Market Cap: Approximately $30 million - Focus: Interventional oncology with a late-stage product in development and a commercial catheter device - Current Stock Price: Approximately $0.75 - Analyst Rating: Buy rating with a price target of $3 per share [1][17] Core Business and Product Development - Product: RenovoCath, a catheter device for localized chemotherapy - Revenue: Achieved $900,000 in revenue through Q3 2025 without a dedicated sales and marketing team [3][13] - Market Potential: Estimated peak sales potential for the catheter is about $400 million [3][8] - Commercialization Strategy: Initiated in early 2025, focusing on understanding market dynamics and barriers to adoption [3][9] Technology and Treatment Approach - Innovative System: Developed a new treatment method called TransArterial Microperfusion (TAMP) for localized chemotherapy [2][5] - Mechanism of Action: Allows for a hundred-fold increase in tissue concentration of chemotherapy compared to systemic delivery [7][8] - Targeted Conditions: Primarily focused on locally advanced pancreatic cancer, with ongoing phase III trials [4][10] Clinical Trials and Efficacy - Phase III Trial: Enrollment expected to complete early next year, with final data anticipated in 2027 [4][14] - Survival Benefits: Interim analysis shows a six-month survival benefit, with patients living approximately 21.5 months compared to 15.5 months in the control group [10][40] - Quality of Life: Notable 65% reduction in systemic toxicities and adverse events compared to traditional therapies [11][40] Market Dynamics and Sales Strategy - Target Market: Approximately 200 hospitals in the U.S. with specialized cancer centers [9] - Sales Force: Currently expanding with the hiring of a Senior Director of Sales and Marketing, along with additional sales representatives [9][20] - Revenue Model: Each patient may require multiple procedures, potentially generating $50,000 to $100,000 in revenue per patient [19][22] Financial Overview - Cash Position: $10 million in cash as of Q3 2025, with a monthly burn rate of $800,000 [16][44] - Profitability Outlook: Positive contribution margin on the device, with a goal to reach break-even with 25-50 hospitals actively using the device [22][23] Future Prospects and Strategic Initiatives - Post-Marketing Registry Study: Launched to track data on the use of RenovoCath across various cancers [12][13] - Expansion Plans: Exploring additional indications and potential partnerships with other biotech firms for drug-device combinations [42][43] - Regulatory Strategy: Aiming for a J-code drug reimbursement for the drug-device combination, which could significantly increase market potential [17] Key Takeaways - RenovoRx is positioned to disrupt traditional cancer treatment paradigms with its innovative localized chemotherapy approach - The company is on track to expand its market presence and revenue generation capabilities through strategic hiring and commercialization efforts - Clinical trial results and a strong focus on quality of life improvements are expected to drive adoption among oncologists and patients alike [10][11][40]